ChapterPDF Available

The Lake Louise Acute Mountain Sickness Scoring System

Authors:
272 ROACH, BARTSCH, et
al
CHAPTER
26
THE LAKE LOUISE ACUTE
MOUNTAIN SICKNESS
SCORING SYSTEM
R.C. Roach, P. Bartsch, P.H. Hackett, O. Oelz
and the Lake Louise AMS Scoring Consensus Committee*
Introduction
In 1991, the Lake Louise Consensus Committee met and agreed on diagnostic
criteria and a scoring system for the symptoms and signs
of
acute mountain sickness!.
The goal was to provide enough sensitivity, specificity and flexibility to allow use
in many different settings and to facilitate comparisons
of
results among all studies
by using this instrument. Since then investigators have used the Lake Louise AMS
scoring system in different settings at different altitudes in several countries. The
previous standard, the Environmental Symptoms Questionnaire (ESQ), has 67 items,
takes time and patience for subjects to complete, and has been resisted by many
researchers2 In contrast, the Lake Louise AMS scoring system takes only a few
minutes to complete and score. Several groups have reported comparable results
regarding sensitivity and specificity between the Lake Louise AMS scoring system
and the
ESQ3-6.
Therefore, we recommend that this scoring system be adapted as
the standard for acute mountain sickness research.
INSTRUCTIONS: The Lake Louise AMS Scoring System
The Lake Louise scoring system consists
of
a short self-report questionnaire,
which
is
sufficient in itself,
or
to which may be added an additional clinical assess-
ment. The AMS Self-report score
is
the sum
of
responses to 5 questions; the find-
ings can be verified by interview
in
the clinical research setting. The Clinical Assess-
ment score is the interviewer's rating
of
three signs: mental status, ataxia and
peripheral edema. This score is added to the AMS Self-report questionnaire score.
An optional question
is
recommended to assess functional consequences
of
recorded
symptoms and signs. The scoring system
is
designed to allow use in both large surveys
and in smaller clinical trials.
Diagnostic Criteria for Acute Mountain Sickness
A diagnosis
of
AMS
is
based on a recent gain in altitude, at least several hours
at the new altitude, and the presence
of
headache and at least one
of
the following
*The Lake Louise AMS Scoring System Consensus Committee: Almas Aldashev, CIS; Buddha Basnyat,
Nepal; A.R. Bradwell, UK; Charles Clark, UK; Geoff Coates, Canada; Allen Cymerman, USA; Allen
Ellsworth, USA; R.F. Fletcher, UK; Eugene Gippenreiter, Russia; Colin Grissom, USA; Ben Honigman,
USA; Charles Houston, USA; Herb Hultgren, USA; Bengt Kayser, Switzerland; Toshio Kobayashi, Japan;
Gig Leadbetter, USA; Marco Maggiorini, Switzerland; N.D. Menon, India; Jim Milledge, UK; C. Carlos
Monge, Peru; Michiro Nakashima, Japan; Dick Nicholas, USA; Drummond Rennie, USA; Jean Paul
Richalet, France; Paul Rock, USA; Roberto Rodriguez Guaita, Chile; David Shlim, Nepal; John Sutton,
Australia;
S.
Takei, Japan; Gou Ueda, Japan;
Ray
Yip, USA.
1993 Roach RC, Bärtsch P, Oelz O, Hackett PH. The Lake Louise Acute
Mountain Sickness Scoring System. In: Sutton JR, Houston CS, Coates G,
Editors. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Press;
1993. p. 272-274.
LAKE LOUISE AMS SCORING SYSTEM
273
symptoms: gastrointestinal upset (anorexia, nausea,
or
vomiting), fatigue or weakness,
dizziness
or
lightheadedness and difficulty sleeping. A score
of
three points
or
greater
on
the AMS Self-report questionnaire alone,
or
in combination with the Clinical
Assessment score constitutes AMS.
A) Self-report questionnaire. This portion
of
the scoring system
is
mandatory
and should be reported as a separate score. Each
of
the following five questions
is asked with the corresponding 0 to 3 rating
of
the response.
In
some studies, the
question "Difficulty sleeping" will not
be
relevant (e.g. rapid one day ascent) and
can be omitted. The sum
of
the responses on these questions is then calculated as
the AMS Self-report score.
It
is recommended that this score be reported separately,
even when used with the Clinical Assessment score. This procedure will allow the
comparisons
of
severity among the majority
of
studies. All will have the AMS Self-
report score, some will have both the AMS Self-report score and the Clinical Assess-
ment score.
1.
Headache. 0 No headache
I Mild headache
2 Moderate headache
3 Severe headache, incapacitating
2.
Gastrointestinal symptoms. 0 No gastrointestinal symptoms
I Poor appetite or nausea
2 Moderate nausea or vomiting
3 Severe nausea & vomiting, incapacitating
3. Fatigue and/or weakness. 0 Not tired or weak
I Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue/weakness, incapacitating
4.
Dizziness/l ightheadedness. 0 Not dizzy
I Mild dizziness
2 Moderate dizziness
3 Severe dizziness, incapacitating
5.
Difficulty sleeping. 0 Slept
as
well
as
usual
I Did not sleep as well as usual
2 Woke many times, poor night's sleep
3 Could not sleep at
all
B)
Clinical Assessment. This portion
of
the scoring system contains information
gained
by
examination. The Clinical Assessment score
is
the sum
of
scores on the follow-
ing three questions.
274 ROACH, BARTSCH, et
al
6.
Change
in
mental status. 0 No change
in
mental status
1 Lethargy/lassitude
2 Disoriented/confused
3 Stupor/semiconsciousness
4 Coma
7. Ataxia (heel to toe walking) 0 No ataxia
1 Maneuvers to maintain balance
2 Steps off line
3 Falls down
4 Can't stand
8.
Peripheral edema. 1 No peripheral edema
1 Peripheral edema
at
one location
2 Peripheral edema at two or more locations
c)
Functional
Score. The functional consequences of the
AMS
Self-reported score
should be further evaluated
by
one optional question asked after the AMS Self-report
questionnaire. Alternatively, this question may be asked by the examiner
if
Clinical
Assessment is performed.
Overall,
if
you had any symptoms, how did they affect your activity?
o No reduction
in
activity
1 Mild reduction
in
activity
2 Moderate reduction
in
activity
3 Severe reduction
in
activity (e.g. bedrest)
References
I. The Lake Louise Consensus on the definition and quantification of altitude illness. In: Hypoxia
and Mountain Medicine, J.R. Sutton, G. Coates, C.S. Houston, editors. Burlington, YT: Queen
City Printers Inc., 1992, p. 327-330.
2. SAMPSON, J.B.,
A.
CYMERMAN, R.L. BURSE, J.T. MAHER, P.
B.
ROCK. Procedures for
the measurement
of
acute mountain sickness. Aviat. Space Environ.
Med.
54(12): 1063-1073, 1983.
3. HONIGMAN, B., J.L. ATKINS, R.C. ROACH, C.S. HOUSTON (Abstract). Acute mountain
sickness
in
the elderly at moderate altitude. In: Proceedings
of
the Eighth International Hypoxia
Symposium, Lake Louise, Canada, 1993.
4. BARTSCH, P.,
A.
MULLER,
D.
HOFSTETTER,
M.
MAGGIORINI,
P.
YOCK, O. OELZ. AMS
and HAPE scoring
in
the Alps (Abstract).
In:
Proceedings
of
the Eighth International Hypoxia Sym-
posium, Lake Louise, Canada, 1993.
5. ELLSWORTH, A., T. DUNCAN,
S.
GOLDBERG, L. JOHNSON, P. HACKETT. Measuring
acute mountain sickness using the Lake Louise Consensus Questionnaire (Abstract).
In:
Proceedings
of
the Eighth International Hypoxia Symposium, J.R. Sutton,
G.
Coates, C.S. Houston, editors.
1993.
6. LEADBETTER,
G.,
R.
ROBERGS,
B.
RUBY, D. LIUM. The effect
of
intermittent altitude ex-
posure on acute mountain sickness (Abstract).
SW
Chapter, Am. Coli. Sports. Med. 1992.
... 2. Moderate AMS as 6-9 points 3. Severe AMS as 10-12 points [10]. ...
... The most significant measure in treatment of worsening acute mountain sickness is early identification and simply descent, if it is a viable option, until symptoms disappear [45]. Substantial changeability among individuals is noticeable, but in most cases, at least 300 m but no more 10 than 1000 m descent is mandatory. If safe reduction of height is not conceivable, there are other interventions that can be used for treatment. ...
Article
Full-text available
Introduction High mountain climbing has surged in popularity over the past few decades, attracting a diverse range of participants from professional athletes to even recreational enthusiasts, given that this sport has become commercial and more accessible. While high mountain climbing offers numerous mental and physical benefits, it also presents significant risks, among them one of the most dangerous is acute mountain sickness (AMS). Correct techniques of prevention are absolutely vital for the success of the expedition. To be able to read correctly the symptoms is essential for making the right decision during hike and knowing how to act once AMS occurs is necessary to ensure safety for all climbers. Aim of the study The purpose of this narrative is to comprehensively describe information about the prevention, symptoms and instructions concerning further procedure while dealing with acute mountain sickness (AMS). Materials and methods The methodology of the literature search involved using the keywords “acute mountain sickness” and adding terms such as “prevention”, “symptoms”, “diagnosis”, “risk factors” and “treatment”. The search terms were entered into the PubMed and Google Scholar databases. The review works and clinical trials were taken into account. Conclusion Acute mountain climbing occurs above 2500 m. The most important aspects of prevention and treatment is controlled ascent, rapid diagnosis and instant initiation of treatment, meaning descent. The pharmacologic prophylaxis and therapy is not recommended in every case, all of the decisions must be taken individually according to severity of symptoms and general situation in the mountains.
... Ascending to altitudes above 2500 m can lead to acute mountain sickness (AMS), which is a common condition characterized by headaches, dizziness, gastrointestinal symptoms (eg, anorexia, nausea, or vomiting), weakness or fatigue, and sleep disturbance. 1 Sleep disturbance is one of the most commonly reported symptoms of acclimatization to hypobaric hypoxia, and it is evaluated using the Lake Louise AMS scoring system. For the sleep quality item, subjects report whether they slept as well as usual (0 points), did not sleep as well as usual (1 point), woke up many times/had a poor night's sleep (2 points), or could not sleep at all (3 points). 1 Restful sleep is essential to perform work optimally the next day. ...
... For the sleep quality item, subjects report whether they slept as well as usual (0 points), did not sleep as well as usual (1 point), woke up many times/had a poor night's sleep (2 points), or could not sleep at all (3 points). 1 Restful sleep is essential to perform work optimally the next day. However, sleep disturbance can worsen headaches and anxiety and cause daytime dysfunction after exposure to high altitudes. ...
Article
Full-text available
Purpose The Athens Insomnia Scale (AIS) is a widely used and authorized questionnaire for evaluating insomnia symptoms. However, its reliability and validity at high altitudes are uncertain. Therefore, this study aimed to confirm the validity and reliability of AIS during a 3658 m altitude exposure. Patients and Methods A total of 387 young Chinese males were enlisted in the acute high-altitude exposure group. They flew for about two hours, climbing from 400 m to 3658 m. The high-altitude-acclimated group consisted of 86 young Chinese men who had lived at least six months at 3658 m altitude. The sleep quality of the acute high-altitude exposure group was evaluated using the AIS before the ascent and after exposure to 3658 m for 24 hours, and one week. The sleep quality of the high-altitude-acclimated group was also assessed. The AIS’s internal consistency, reliability, and validity were evaluated. Results The respondents’ quality of sleep significantly decreased after being exposed to 3658 m as opposed to 400 m. Two factors comprised the AIS, according to an exploratory factor analysis: “sleep problem” (items 1–5) and “daytime dysfunction” (items 6–8). The Cronbach’s α internal consistency coefficients exceeded 0.8, and the corrected item-total correlations were all greater than 0.5 when the subjects were exposed to 3658 m. The model fit index was well within the criterion. The average variance extracted and composite reliability were all higher than 0.5 and 0.7, respectively. The interclass correlation coefficient was deemed “fair to good” at 0.482, which is greater than the 0.4 threshold. The AIS has satisfactory discriminant validity, as shown by the Fornell-Larcker criterion and cross-loading results. The daytime dysfunction R-square values (>0.33) show that the frameworks have considerable predictive accuracy. Conclusion The AIS exhibits strong consistency, reliability, and validity. The AIS’s features and simplicity make it an essential psychometric tool for high-altitude sleep research.
... Rapid ascent to altitudes above 2500 m may lead to acute mountain sickness [AMS], 1 which is a common syndrome including headache, dizziness or lightheadedness, gastrointestinal symptoms (anorexia, nausea, or vomiting), weakness or fatigue, and insomnia. 2 Although AMS is generally self-limited, it can develop into life-threatening high-altitude pulmonary or/and cerebral oedema. 3 In addition, the precise pathogenesis of AMS remains incompletely understood. ...
Article
Full-text available
Purpose We aimed to explore whether anxiety is a risk factor for acute mountain sickness [AMS] in a young Chinese male population. Patients and Methods A total of 143 young Chinese men with a median age of 23 years (IQR, 21–25) were employed in the present study, and they were divided into the AMS+ and AMS- groups according to the Lake Louise AMS score [AMS-S] after exposure at 3800 m for two days. Participants’ pulse oximeter saturation [SpO2] and heart rate [HR] were measured. AMS was evaluated using the AMS-S. The anxiety and sleep quality of the subjects were assessed using the Zung Self-Rating Anxiety Scale [SAS] and the Athens Insomnia Scale [AIS], respectively. Outcomes were analysed using Spearman’s partial correlation and logistic regression analysis. Results After two days of exposure at 3800 m, the overall prevalence of AMS was 54% in the whole group. The HR was significantly higher in the AMS+ group than in the AMS- group, as well as the SAS score and AIS score. A converse pattern was observed for SpO2. A significant difference was observed for the change in SAS and AIS score between the AMS+ and AMS- groups. Correlation analysis showed that AMS-S was positively correlated with SAS score, AIS score, HR, ΔSAS score, ΔAIS score, and ΔHR but negatively correlated with SpO2. AIS score was positively correlated with SAS score. After logistic regression analysis was adjusted for HR, SpO2, ΔAIS and ΔHR, SAS score (OR=1.446, 95% CI 1.200–1.744, p<0.001), AIS score (OR=1.216, 95% CI 1.033–1.432) and ΔSAS score (OR=1.158, 95% CI 1.012–1.327) were identified as independent risk factors for AMS. Conclusion The present study suggests that anxiety is a risk factor for AMS among young Chinese men, and poor sleep quality may partially mediate the association.
... Lake Louise Score (LLS) questionnaire for AMS evaluation: The Lake Louise Score included five different symptoms: headache, gastrointestinal symptoms, fatigue, dizziness, and difficulty sleeping. Each was graded from 0 to 3 in severity, with higher values indicating more severe altitude sickness [40]. ...
Article
Full-text available
Intermittent hypoxia training (IHT) is a promising approach that has been used to induce acclimatization to hypoxia and subsequently lower the risk of developing acute mountain sickness (AMS). However, the effects of IHT on cognitive and cerebrovascular function after acute hypoxia exposure have not been characterized. In the present study, we first confirmed that the simplified IHT paradigm was effective at relieving AMS at 4300 m. Second, we found that IHT improved participants’ cognitive and neural alterations when they were exposed to hypoxia. Specifically, impaired working memory performance, decreased conflict control function, impaired cognitive control, and aggravated mental fatigue induced by acute hypoxia exposure were significantly alleviated in the IHT group. Furthermore, a reversal of brain swelling induced by acute hypoxia exposure was visualized in the IHT group using magnetic resonance imaging. An increase in cerebral blood flow (CBF) was observed in multiple brain regions of the IHT group after hypoxia exposure as compared with the control group. Based on these findings, the simplified IHT paradigm might facilitate hypoxia acclimatization, alleviate AMS symptoms, and increase CBF in multiple brain regions, thus ameliorating brain swelling and cognitive dysfunction.
... Particularly during the early phase of hypoxic exposure, both hypoxia per se and AMS likely influence appetite, since a symptom of AMS is loss of appetite (Roach et al., 1993). When assessing appetite and food preferences in hypoxia it is, therefore, necessary to assess AMS. ...
Article
Barclay, Holly, Saptarshi Mukerji, Bengt Kayser, and Jui-Lin Fan. Appetite, hypoxia and acute mountain sickness: A 10-hour normobaric hypoxic chamber study. High Alt Med Biol. 24:000-000, 2023. Background: The effects of hypoxia and acute mountain sickness (AMS) on appetite and food preferences are moot, especially during the early phase of hypoxic exposure. We examined the effects of a 10-hour hypoxic exposure on appetite and food preference. Methods: We assessed appetite (hunger, satisfaction, fullness, perceived appetite, and lost appetite), food preferences (sweet, salty, savory, and fatty), and AMS (Lake Louise score) with questionnaires in 27 healthy individuals (13 women) across 10-hour exposures to normobaric normoxia (fraction of inspired O2 [FiO2]: 0.21) and normobaric hypoxia (FiO2: 0.12, equivalent of 5,000 m) in a randomized, single-blinded manner. Results and Discussion: Compared with normoxia, hypoxia decreased hunger and appetite (p = 0.040 and <0.001, respectively), which was mediated by a decreased desire for sweet, salty, and fatty foods (p < 0.05 for all). AMS was associated with a decreased desire for sweet (R = -0.438, p = 0.032) and salty foods (R = -0.460, p = 0.024) and greater loss of appetite (R = -0.619, p = 0.018). Our findings suggest that acute hypoxia rapidly suppresses appetite and that AMS development further amplifies anorexia. Clinical Trial Registration Number: ACTRN12618000548235.
... 36 The Lake Louise questionnaire was also completed every morning upon waking to assess acute mountain sickness severity. 37 The questionnaires were averaged across the camp to provide a group score. ...
Article
Purpose: To investigate the effects of a training camp with heat and/or hypoxia sessions on hematological and thermoregulatory adaptations. Methods: Fifty-six elite male rugby players completed a 2-week training camp with 5 endurance and 5 repeated-sprint sessions, rugby practice, and resistance training. Players were separated into 4 groups: CAMP trained in temperate conditions at sea level, HEAT performed the endurance sessions in the heat, ALTI slept and performed the repeated sprints at altitude, and H + A was a combination of the heat and altitude groups. Results: Blood volume across all groups increased by 140 mL (95%CI, 42-237; P = .006) and plasma volume by 97 mL (95%CI 28-167; P = .007) following the training camp. Plasma volume was 6.3% (0.3% to 12.4%) higher in HEAT than ALTI (P = .034) and slightly higher in HEAT than H + A (5.6% [-0.3% to 11.7%]; P = .076). Changes in hemoglobin mass were not significant (P = .176), despite a ∼1.2% increase in ALTI and H + A and a ∼0.7% decrease in CAMP and HEAT. Peak rectal temperature was lower during a postcamp heat-response test in HEAT (0.3 °C [0.1-0.5]; P = .010) and H + A (0.3 °C [0.1-0.6]; P = .005). Oxygen saturation upon waking was lower in ALTI (3% [2% to 5%]; P < .001) and H + A (4% [3% to 6%]; P < .001) than CAMP and HEAT. Conclusion: Although blood and plasma volume increased following the camp, sleeping at altitude impeded the increase when training in the heat and only marginally increased hemoglobin mass. Heat training induced adaptations commensurate with partial heat acclimation; however, combining heat training and altitude training and confinement during a training camp did not confer concomitant hematological adaptations.
... The incidence of AMS was evaluated with the Lake Louise AMS Scoring system (LLS) on M2-M5. The LLS is a self-reported questionnaire consisting of five questions on typical AMS symptoms including headache, gastrointestinal symptoms, fatigue/weakness, dizziness/light-headedness and sleep (Roach et al. 1993). Urine was collected continuously throughout both sojourns and TBW was measured over the last night by deuterium dilution. ...
Article
Kammerer, Tobias, Anna Walzl, Thomas Müller, Philipp Groene, Giulia Roveri, Rachel Turner, Johanna Roche, Hannes Gatterer, Christoph Siebenmann, and Simon T. Schäfer. Effects of hypobaric hypoxia on coagulation in healthy subjects exposed to 3,500 m altitude. High Alt Med Biol. 24:94-103, 2023. Background: Hypoxia is discussed as a trigger for prothrombotic changes both in intensive care and high altitude medicine. This research study aimed to evaluate the effect of isolated hypobaric hypoxia (HH) on coagulation in females in a highly standardized setting. Methods: Twelve healthy female subjects were studied under HH (equivalent to 3,500 m) and normoxia (NX) during two 4-day sojourns, in a strictly controlled crossover design. Nutrition, fluid intake, hormonal status (i.e., menstrual cycle variation), and physical stress were standardized. Functional coagulation and blood lysis were measured by viscoelastometry and compared between HH and NX. In addition, plasma-based coagulation tests (PBCTs), namely prothrombin time, activated partial thromboplastin time, fibrinogen, factor VIII coagulation activity (FVIII:C), von Willebrand factor antigen (vWF:Ag), and von Willebrand factor ristocetin cofactor activity (vWF:RCo) were measured. Results: Neither for Viscoelastic Haemostatic Assays nor for PBCTs significant changes were found for HH compared with NX (all p > 0.05). Specifically, the lysis ability, as well as clotting time, clot formation, clot amplitude, and maximum clot firmness unchanged were similar between HH and NX. This also applied to all other variables. Conclusion: We demonstrate that moderate HH per se has no influence on blood coagulation in healthy females.
Article
Every year millions of people fly to high-altitude destinations. They thereby expose themselves to specific high-altitude conditions. The hypoxic environment (low ambient oxygen availability) constitutes a major factor affecting health and well-being at high altitude. While the oxygen availability is already moderately reduced inside the aircraft cabin, this reduction becomes aggravated when leaving the plane at high-altitude destinations. Especially if not pre-acclimatized, the risk of suffering from high-altitude illnesses, e.g., acute mountain sickness, high-altitude cerebral or pulmonary edema, increases with the level of altitude. In addition, diminished oxygen availability impairs exercise tolerance, which not only limits physical activity at high altitude but may also provoke symptomatic exacerbation of pre-existing diseases. Moreover, the cold and dry ambient air and increased levels of solar radiation may contribute to adverse health effects at higher altitude. Thus, medical pre-examination and pre-flight advice, and proper preparation (pre-acclimatization, exercise training, and potentially adaptation of pharmacological regimes) are of utmost importance to reduce negative health impacts and frustrating travel experiences.
Article
Full-text available
Background: Hypoxia and old age impair postural control and may therefore enhance the risk of accidents. We investigated whether acetazolamide, the recommended drug for prevention of acute mountain sickness, may prevent altitude-induced deterioration of postural control in older persons. Methods: In this parallel-design trial, 95 healthy volunteers, 40 years of age or older, living <1,000 m, were randomized to preventive therapy with acetazolamide (375 mg/d) or placebo starting 24 h before and during a 2-day sojourn at 3,100 m. Instability of postural control was quantified by a balance platform with the center of pressure path length (COPL) as primary outcome while pulse oximetry (SpO2) was monitored. Effects of altitude and treatment on COPL were evaluated by ordered logistic regression. www.ClinicalTrials.gov NCT03536429. Results: In participants taking placebo, ascent from 760 m to 3,100 m increased median COPL from 25.8 cm to 27.6 cm (odds ratio 3.80, 95%CI 2.53–5.70) and decreased SpO2 from 96% to 91% (odds ratio 0.0003, 95%CI 0.0002–0.0007); in participants taking acetazolamide, altitude ascent increased COPL from 24.6 cm to 27.3 cm (odds ratio 2.22, 95%CI 1.57–3.13), while SpO2 decreased from 96% to 93% (odds ratio 0.007, 95%CI 0.004–0.012). Altitude-induced increases in COPL were smaller with acetazolamide vs. placebo (odds ratio 0.58, 95%CI 0.34–0.99) while drops in SpO2 were mitigated (odds ratio 19.2, 95%CI 9.9–37.6). Conclusion: In healthy individuals, 40 years of age or older, postural control was impaired after spending a night at 3,100 m. The altitude-induced deterioration of postural control was mitigated by acetazolamide, most likely due to the associated improvement in oxygenation.
Article
Although acute mountain sickness (AMS) has been studied for well over a century, a standard measure or index of the degree of illness for use in experimental research does not exist. This paper outlines a definition and procedures for an operational measurement of AMS using the Environmental Symptoms Questionnaire (ESQ). After 58 men completed over 650 ESQs during a stay of 1-3 weeks atop Pike's Peak (4300 m), factor analysis produced nine distinct symptom groups, with two factors representing AMS. The first factor contains symptoms indicative of cerebral hypoxia and is labeled AMS-C. The second reflects respiratory distress and is called AMS-R. Signal detection theory was used to establish a criterion score value for each factor. Standard deviation values were used to derive indices of sickness severity. Discussion is given to the possible relationships between the two types of AMS and the more serious conditions of cerebral and pulmonary edema.
Measuring acute mountain sickness using the Lake Louise Consensus Questionnaire (Abstract)
  • A Ellsworth
  • T Duncan
  • S Goldberg
  • L Johnson
  • P Hackett
ELLSWORTH, A., T. DUNCAN, S. GOLDBERG, L. JOHNSON, P. HACKETT. Measuring acute mountain sickness using the Lake Louise Consensus Questionnaire (Abstract). In: Proceedings of the Eighth International Hypoxia Symposium, J.R. Sutton, G. Coates, C.S. Houston, editors. 1993.
The effect of intermittent altitude exposure on acute mountain sickness (Abstract)
  • G Leadbetter
  • R Robergs
  • B Ruby
LEADBETTER, G., R. ROBERGS, B. RUBY, D. LIUM. The effect of intermittent altitude exposure on acute mountain sickness (Abstract). SW Chapter, Am. Coli. Sports. Med. 1992.
Acute mountain sickness in the elderly at moderate altitude
  • B Honigman
  • J L Atkins
  • R C Roach
  • C S Houston
HONIGMAN, B., J.L. ATKINS, R.C. ROACH, C.S. HOUSTON (Abstract). Acute mountain sickness in the elderly at moderate altitude. In: Proceedings of the Eighth International Hypoxia Symposium, Lake Louise, Canada, 1993.